ContraFect to Participate in World Antimicrobial Resistance Congress 2018
October 22 2018 - 5:00PM
ContraFect Corporation
(Nasdaq:CFRX), a clinical-stage biotechnology
company focused on the discovery and development of protein and
antibody therapeutics for life-threatening, drug-resistant
infectious diseases, today announced that Steven C. Gilman, Ph.D.,
the Company’s Chairman and Chief Executive Officer, will
participate in a keynote address entitled “Can non-traditional be
our next line of defense? Challenges in non-traditional
development, stewardship and diagnostic approaches” at the World
Antimicrobial Resistance Congress 2018 on Friday, October 26, 2018
at 9:45 AM ET in Washington, D.C.
Topics of the keynote address include: the most promising and
commercially viable non-traditional therapeutics in the pipeline;
action plans for further development, partnered diagnostic
development, and stewardship implications; clinical trial
regulation and approval pathways for non-traditional therapeutics;
and regulator, industry and payer involvement in new and
non-traditional therapeutics. Dr. Gilman will provide industry
perspective on the development of alternative therapeutics to treat
bacterial infections.
About ContraFect:
ContraFect is a biotechnology company focused on discovering and
developing therapeutic protein and antibody products for
life-threatening, drug-resistant infectious diseases, particularly
those treated in hospital settings. An estimated 700,000 deaths
worldwide each year are attributed to antimicrobial-resistant
infections. We intend to address life threatening infections using
our therapeutic product candidates from our lysin and monoclonal
antibody platforms to target conserved regions of either bacteria
or viruses (regions that are not prone to mutation). ContraFect's
initial product candidates include new agents to treat
antibiotic-resistant infections such as MRSA (Methicillin-resistant
Staph aureus) and influenza. ContraFect’s lead product candidate,
CF-301, is currently in a Phase 2 clinical trial for the treatment
of Staphylococcus aureus bacteremia, including endocarditis and is
the first lysin to enter clinical studies in the U.S.
ContraFect is also conducting research focused on the discovery of
lysins to target Gram-negative bacteria.
Forward-Looking
Statements:
This press release contains, and our officers and
representatives may make from time to time, “forward-looking
statements” within the meaning of the U.S. federal securities
laws. Forward-looking statements can be identified by words
such as “projects,” “may,” “will,” “could,” “would,” “should,”
“believes,” “expects,” “anticipates,” “estimates,” “intends,”
“plans,” “potential,” “promise” or similar references to future
periods. Examples of forward-looking statements in this release
include, without limitation, statements regarding our ability to
discover and develop protein and antibody therapeutics for
life-threatening, drug-resistant infectious diseases, our ability
to address life threatening infections using our therapeutic
product candidates from our lysin and monoclonal antibody platforms
to target conserved regions of either bacteria or viruses, whether
our initial product candidates can treat antibiotic-resistant
infections such as MRSA and influenza, our ability to discover new
lysins targeting Gram-negative bacteria, the potential for CF-301
to be a treatment for Staph aureus bacteremia, including
endocarditis, and statements made regarding the keynote address.
Forward-looking statements are statements that are not historical
facts, nor assurances of future performance. Instead, they are
based on ContraFect’s current beliefs, expectations and assumptions
regarding the future of its business, future plans, strategies,
projections, anticipated events and trends, the economy and other
future conditions. Because forward-looking statements relate to the
future, they are subject to inherent risks, uncertainties and
changes in circumstances that are difficult to predict and many of
which are beyond ContraFect’s control, including those detailed in
ContraFect's filings with the Securities and Exchange
Commission. Actual results may differ from those set forth in
the forward-looking statements. Important factors that could cause
actual results to differ include, among others, our ability to
develop treatments for drug-resistant infectious diseases. Any
forward-looking statement made by ContraFect in this press release
is based only on information currently available and speaks only as
of the date on which it is made. Except as required by applicable
law, ContraFect expressly disclaims any obligations to publicly
update any forward-looking statements, whether written or oral,
that may be made from time to time, whether as a result of new
information, future developments or otherwise.
Investor Relations Contacts:
Michael MessingerContraFect CorporationTel: 914-207-2300Email:
mmessinger@contrafect.com
Matthew ShinsekiStern Investor RelationsTel: 212-362-1200Email:
matthew@sternir.com
ContraFect (NASDAQ:CFRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
ContraFect (NASDAQ:CFRX)
Historical Stock Chart
From Apr 2023 to Apr 2024